ClinicalTrials.gg
CompletedNCT00933686Updated Aug 2, 2013Results posted

Growth Hormone in Neuroendocrine Dysfunction With Severe Fibromyalgia Syndrome

A Phase 3 interventional study of Saizen® and Placebo and Saizen® in Fibromyalgia, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-08-02.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
113
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 151 studies in Fibromyalgia with a site in Spain — 16 open to participants now, 21 under way, none of them phase 3. Fibromyalgia · Spain.

Enrollment
34th of 135
113 · median 66
Started
2007
with 4 others
Phase 3
14 of 151
none open now
Registered
15th of 151
by date

Among the 151 studies in Fibromyalgia with a site in Spain, this one is the 34th largest by enrollment of the 135 interventional ones that give a count, is one of 5 that started in 2007, is one of 14 in phase 3, and was the 15th registered.

Fibromyalgia

1,244 studies on the registry are indexed under Fibromyalgia; 255 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

16 of the 151 studies in Fibromyalgia with a site in Spain are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 160 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies in Fibromyalgia with a site in Spain, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of recombinant human growth hormone (r-hGH) treatment in severe fibromyalgia subjects with growth axis dysfunction.

03

Conditions studied

  • Fibromyalgia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged greater than or equal (>=) 18 years
  • Fibromyalgia diagnosed at least one year before
  • History of generalized pain and at least 16 positive tender points (1990 American College of Rheumatology [ACR] criteria)
  • (BMI) less than or equal to(=\<) 32
  • Normal GH stimulation test (insulin)
  • Stable (>= 3 months unchanged) standard treatment with amitriptyline (10-50 milligram per day [mg/day]) plus selective serotonin reuptake inhibitor (10-40 mg/day) plus tramadol (25-400 mg/day)
  • Active rehabilitation program during the previous year (at least 30 minutes/day)
  • Fibromyalgia Impact Questionnaire (FIQ) score >=75
  • IGF-1 serum level =\< 150 nanogram/milliliter (ng/mL) otherwise =\< 2 SD of the local lab normality)
  • Normal response to IGF-1 generation test
  • Chronic Fatigue Symptoms (Multidimensional Assessment of Fatigue [MAF])
  • Effective anti-conception
  • Willingness to comply with the protocol
  • Written

Exclusion criteria

Exclusion Criteria:

  • Major psychiatric condition
  • Rheumatic disease, including systemic lupus erythematosus (SLE)
  • Previous or current , active or inactive
  • Clinical history intracranial space occupying lesion
  • Reactive or secondary (rheumatoid arthritis [RA], osteoarthritis) fibromyalgia syndrome (FMS)
  • Antinuclear antibody (ANA) greater than or equal 1:80
  • Abnormal Creatine phosphokinase (CPK) or aldolase serum levels
  • Not controlled thyroid disease in the last 3 months (free Thyroxine [T4] and Thyrotrophin-stimulating hormone [TSH] serum levels)
  • Diabetes mellitus
  • Adrenal gland disease (any abnormal cortisolemia, will be confirmed by 24-hour cortisoluria)
  • Pregnancy or breast feeding
  • Known to be hypersensitive to somatotropin or any of the
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
113 participants (actual)

Study arms

  • Active comparator
    Saizen®

    Drug: Saizen®

  • Active comparator
    Placebo + Saizen®

    Drug: Placebo and Saizen®

Interventions

  • DrugHuman Growth HormoneStudies of Human Growth HormoneHuman Growth Hormone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Saizen® (Somatropin) 0.006 milligram per kilogram (mg/kg) will be administered subcutaneously daily for 12 months. Dose will be titrated (an increase of 0.2 milligram per day) if the increase in insulin-like growth factor 1 (IGF-1) is less than 50 percent of the baseline value. Dose titrations will be made at Month 1, 3, 7 and 9.

    Also known as: Somatropin

  • DrugPlacebo and Saizen®

    Placebo matched to Saizen® will be administered for the first 6 months followed by treatment with Saizen® (Somatropin) 0.006 mg/kg subcutaneously daily for next 6 months. Saizen® dose will be titrated (an increase of 0.2 milligram per day) if the increase in insulin-like growth factor 1 (IGF-1) is less than 50 percent of the baseline value. Dose titrations will be made at Month 7 and 9.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Less Than 11 Tender Points at Month 6

    The musculoskeletal component in form of pain on palpation in at least 11 of 18 tender point sites is required to fulfill the American College of Rheumatology (ACR) criteria for fibromyalgia syndrome, An important response is considered when the number of tender points falls below 11 since it is the threshold for fibromyalgia diagnosis.

    Time frame: Month 6

  2. Percentage of Participants With Less Than 11 Tender Points at Month 12

    The musculoskeletal component in form of pain on palpation in at least 11 of 18 tender point sites is required to fulfill the ACR criteria for fibromyalgia syndrome, An important response is considered when the number of tender points falls below 11 since it is the threshold for fibromyalgia diagnosis.

    Time frame: Month 12

Secondary outcomes

  1. Fibromyalgia Impact Questionnaire (FIQ) Total Score

    Fibromyalgia Impact Questionnaire (FIQ) is a 10-item questionnaire that measures physical impairment, well-being, missed work, pain, fatigue, rest, stiffness, anxiety, and depression. Score ranges from 0 (best result - very well) to 100 (worst result - awful).

    Time frame: Baseline, Month 1, 3, 6, 7, 9 and 12

  2. Visual Analog Scale (VAS) Total Score

    Visual Analog Scale (VAS) is a 100 millimeter (mm) scale. Intensity of pain range: 0 mm=no pain to 100 mm=worst possible pain.

    Time frame: Baseline, Month 1, 3, 6, 7, 9 and 12

  3. EuroQol 5-Dimensions (EQ-5D) Total Score

    EuroQol 5-Dimensions (EQ-5D) questionnaire is a measure of health status and quality of life (QoL). The EQ-5D defines health in terms of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Score range for each item is 0 to 3, with 3 being the most severe. Total score range is 0 to 15. Lower scores represent a better QoL.

    Time frame: Baseline, Month 1, 3, 6, 7, 9 and 12

  4. Multidimensional Assessment of Fatigue (MAF) Total Score

    Multidimensional Assessment of Fatigue (MAF) consists of 16 questions. The score range for first 14 questions is between 0 and 10 for each question while for the last two questions it is 0 and 4 for each question. Total score range for first 14 questions is 0 to 100 and for last two questions is 0 to 8. Lower scores on the each represent the better participant's condition, whereas, higher scores indicate worsening condition.

    Time frame: Baseline, Month 6 and 12

  5. Percentage of Participants With Positive Response on Quality of Life Assessment of Growth Hormone [GH] Deficiency in Adults (QoL AGHDA) Scale

    Quality of Life Assessment of GH Deficiency in Adults (QoL AGHDA) questionnaire consists of 25 items that evoke yes or no answers. A score of 1 is given to each item affirmed and these are summed to give the total score. The maximum score is 25, which represents a poor quality of life. The minimum score is 0, which represents a good quality of life. Each question has to be answered with a NO/YES and for each YES, one point is added. The more YES, the higher the score and the worse. Decrease in the positive responses is an index of improvement. So, when the percentage of positive responses on the scale decreases, it is considered a response rate.

    Time frame: Baseline, Month 6 and 12

07

Results

Posted Aug 2, 2013

Participant flow

123 subjects were enrolled of whom 113 subjects were randomised and treated.

Participant flow — Overall Study
MilestoneSaizen®Placebo + Saizen®
Started5558
Completed4547
Not completed1011
Withdrew: Protocol violation01
Withdrew: Lost to follow-up22
Withdrew: Withdrawal by subject65
Withdrew: Adverse event11
Withdrew: Physician decision10
Withdrew: Failure to show up at endpoint visits02

Outcome measures

PrimaryPercentage of Participants With Less Than 11 Tender Points at Month 6

The musculoskeletal component in form of pain on palpation in at least 11 of 18 tender point sites is required to fulfill the American College of Rheumatology (ACR) criteria for fibromyalgia syndrome, An important response is considered when the number of tender points falls below 11 since it is the threshold for fibromyalgia diagnosis.

Time frame:
Month 6
Reported as:
Number · Percentage of participants
Percentage of Participants With Less Than 11 Tender Points at Month 6
Percentage of participantsSaizen®Placebo + Saizen®
Percentage of Participants With Less Than 11 Tender Points at Month 62022
PrimaryPercentage of Participants With Less Than 11 Tender Points at Month 12

The musculoskeletal component in form of pain on palpation in at least 11 of 18 tender point sites is required to fulfill the ACR criteria for fibromyalgia syndrome, An important response is considered when the number of tender points falls below 11 since it is the threshold for fibromyalgia diagnosis.

Time frame:
Month 12
Reported as:
Number · Percentage of participants
Percentage of Participants With Less Than 11 Tender Points at Month 12
Percentage of participantsSaizen®Placebo + Saizen®
Percentage of Participants With Less Than 11 Tender Points at Month 125334
SecondaryFibromyalgia Impact Questionnaire (FIQ) Total Score

Fibromyalgia Impact Questionnaire (FIQ) is a 10-item questionnaire that measures physical impairment, well-being, missed work, pain, fatigue, rest, stiffness, anxiety, and depression. Score ranges from 0 (best result - very well) to 100 (worst result - awful).

Time frame:
Baseline, Month 1, 3, 6, 7, 9 and 12
Reported as:
Mean · Units on a scale
Fibromyalgia Impact Questionnaire (FIQ) Total Score
Units on a scaleSaizen®Placebo + Saizen®
Baseline (n=54, 57)85.7 ± 2.386.0 ± 1.8
Month 1 (n=52, 54)74.6 ± 3.673.3 ± 4.7
Month 3 (n=52, 54)72.1 ± 4.466.4 ± 5.1
Month 6 (n=51, 50)65.8 ± 4.868.4 ± 5.3
Month 7 (n=51, 50)59.2 ± 5.565.8 ± 5.7
Month 9 (n=51, 50)58.2 ± 6.465.1 ± 5.7
Month 12 (n=45, 47)52.5 ± 6.564.7 ± 6.5
SecondaryVisual Analog Scale (VAS) Total Score

Visual Analog Scale (VAS) is a 100 millimeter (mm) scale. Intensity of pain range: 0 mm=no pain to 100 mm=worst possible pain.

Time frame:
Baseline, Month 1, 3, 6, 7, 9 and 12
Reported as:
Mean · mm
Visual Analog Scale (VAS) Total Score
mmSaizen®Placebo + Saizen®
Baseline (n=54, 57)73.3 ± 3.474.3 ± 3.1
Month 1 (n=52, 54)65.1 ± 4.268.0 ± 5.7
Month 3 (n=52, 54)63.7 ± 5.658.4 ± 5.8
Month 6 (n=51, 50)57.6 ± 5.760.4 ± 6.6
Month 7 (n=51, 50)54.6 ± 5.256.1 ± 6.2
Month 9 (n=51, 50)51.2 ± 6.760.3 ± 6.3
Month 12 (n=45, 47)45.0 ± 6.960.6 ± 6.0
SecondaryEuroQol 5-Dimensions (EQ-5D) Total Score

EuroQol 5-Dimensions (EQ-5D) questionnaire is a measure of health status and quality of life (QoL). The EQ-5D defines health in terms of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Score range for each item is 0 to 3, with 3 being the most severe. Total score range is 0 to 15. Lower scores represent a better QoL.

Time frame:
Baseline, Month 1, 3, 6, 7, 9 and 12
Reported as:
Mean · Units on a scale
EuroQol 5-Dimensions (EQ-5D) Total Score
Units on a scaleSaizen®Placebo + Saizen®
Baseline (n=54, 57)11.07 ± 0.4411.24 ± 0.42
Month 1 (n=52, 54)10.46 ± 0.4510.45 ± 0.42
Month 3 (n=52, 54)10.13 ± 0.4510.06 ± 0.55
Month 6 (n=51, 50)10.00 ± 0.4810.16 ± 0.56
Month 7 (n=51, 50)9.63 ± 0.499.77 ± 0.54
Month 9 (n=51, 50)9.49 ± 0.609.80 ± 0.50
Month 12 (n=45, 47)9.09 ± 0.649.94 ± 0.56
SecondaryMultidimensional Assessment of Fatigue (MAF) Total Score

Multidimensional Assessment of Fatigue (MAF) consists of 16 questions. The score range for first 14 questions is between 0 and 10 for each question while for the last two questions it is 0 and 4 for each question. Total score range for first 14 questions is 0 to 100 and for last two questions is 0 to 8. Lower scores on the each represent the better participant's condition, whereas, higher scores indicate worsening condition.

Time frame:
Baseline, Month 6 and 12
Reported as:
Number · Units on a scale
Multidimensional Assessment of Fatigue (MAF) Total Score
Units on a scaleSaizen®Placebo + Saizen®
1 to 14 questions: Baseline (n=54, 57)9083
1 to 14 questions: Month 6 (n=51, 50)8578
1 to 14 questions: Month 12 (n=45, 47)7378
15 and 16 question: Baseline (n=54, 57)77
15 and 16 question: Month 6 (n=51, 50)66
15 and 16 question: Month 12 (n=45, 47)56
SecondaryPercentage of Participants With Positive Response on Quality of Life Assessment of Growth Hormone [GH] Deficiency in Adults (QoL AGHDA) Scale

Quality of Life Assessment of GH Deficiency in Adults (QoL AGHDA) questionnaire consists of 25 items that evoke yes or no answers. A score of 1 is given to each item affirmed and these are summed to give the total score. The maximum score is 25, which represents a poor quality of life. The minimum score is 0, which represents a good quality of life. Each question has to be answered with a NO/YES and for each YES, one point is added. The more YES, the higher the score and the worse. Decrease in the positive responses is an index of improvement. So, when the percentage of positive responses on the scale decreases, it is considered a response rate.

Time frame:
Baseline, Month 6 and 12
Reported as:
Number · Percentage of participants
Percentage of Participants With Positive Response on Quality of Life Assessment of Growth Hormone [GH] Deficiency in Adults (QoL AGHDA) Scale
Percentage of participantsSaizen®Placebo + Saizen®
Baseline (n=54, 57)7372
Month 6 (n=51, 50)7069
Month 12 (n=45, 47)5970

Adverse events

Collected over Baseline up to Month 12. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Saizen®—4/55 (7.3%)45/55 (81.8%)
Placebo + Saizen®—0/58 (0%)51/58 (87.9%)
Most frequent serious events
Most frequent serious events
EventSaizen®Placebo + Saizen®
Cervix carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/550/58
Sleep apnoea syndromeNervous system disorders1/550/58
Abdominal pain lowerGastrointestinal disorders1/550/58
Food allergyImmune system disorders1/550/58
Most frequent other events
Showing 10 of 122
Most frequent other events
EventSaizen®Placebo + Saizen®
HeadacheNervous system disorders21/5513/58
OedemaMusculoskeletal and connective tissue disorders17/5515/58
FibromyalgiaMusculoskeletal and connective tissue disorders1/5516/58
ParaesthesiaNervous system disorders13/556/58
InsomniaNervous system disorders9/552/58
Carpal tunnel syndromeNervous system disorders8/557/58
TachycardiaCardiac disorders0/558/58
HypertriglyceridaemiaMetabolism and nutrition disorders0/558/58
ArthralgiaMusculoskeletal and connective tissue disorders4/558/58
Urinary tract infectionRenal and urinary disorders7/551/58

Baseline characteristics

Age Continuous
Age Continuous(years)Saizen®Placebo + Saizen®Total
Mean49.9 ± 9.550.3 ± 9.650.1 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)Saizen®Placebo + Saizen®Total
Female5558113
Male000
08

Study locations

1 site
  • Centro Medico Teknon, Endocrinology Department
    Barcelona, Spain
09

References and documents

Publications

  • Cuatrecasas G, Alegre C, Fernandez-Sola J, Gonzalez MJ, Garcia-Fructuoso F, Poca-Dias V, Nadal A, Cuatrecasas G, Navarro F, Mera A, Lage M, Peino R, Casanueva F, Linan C, Sesmilo G, Coves MJ, Izquierdo JP, Alvarez I, Granados E, Puig-Domingo M. Growth hormone treatment for sustained pain reduction and improvement in quality of life in severe fibromyalgia. Pain. 2012 Jul;153(7):1382-1389. doi: 10.1016/j.pain.2012.02.012. Epub 2012 Mar 31. PubMed 22465047 ↗
  • Cuatrecasas G, Gonzalez MJ, Alegre C, Sesmilo G, Fernandez-Sola J, Casanueva FF, Garcia-Fructuoso F, Poca-Dias V, Izquierdo JP, Puig-Domingo M. High prevalence of growth hormone deficiency in severe fibromyalgia syndromes. J Clin Endocrinol Metab. 2010 Sep;95(9):4331-7. doi: 10.1210/jc.2010-0061. Epub 2010 Jul 14. PubMed 20631018 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 3 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2009
First posted
Jul 7, 2009
Start
Dec 2007
Primary completionActual
Jul 2010
CompletionActual
Jul 2010
Results first posted
Aug 2, 2013
Last update
Aug 2, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00933686
Collaborators
Merck, S.L., Spain
Responsible party
Sponsor
First posted
Jul 7, 2009
Start date
Dec 2007
Primary completion
Jul 2010
Completion
Jul 2010
Results posted
Aug 2, 2013
Last update
Aug 2, 2013

Study contacts

Guillem Cuatrecasas, MD
principal investigator · Centro Medico Teknon

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion